Clinical trial • Phase I • Oncology
MAT2A inhibitor for Advanced solid tumors
Phase I trial of MAT2A inhibitor for Advanced solid tumors. open-label. 85 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 15-02-2024
- First CTIS Authorization Date
- 21-03-2024
Trial design
open-label Phase I trial in France, Germany, Spain.
- Open Label
- Yes
- Target Sample Size
- 85
Recruitment
- Planned Sample Size
- 85
- Recruitment Window Months
- 52
Geography
- Total Number Of Sites
- 14
- Total Number Of Participants
- 45
France
- Earliest CTIS Part Ii Submission Date
- 28-02-2024
- Latest Decision Or Authorization Date
- 02-02-2026
- Processing Time Days
- 705
- Number Of Sites
- 6
- Number Of Participants
- 15
Sites
- Site Name
- Centre Hospitalier Regional De Marseille
- Department Name
- CEPCM
- Contact Person Name
- Laurent Greillier
- Contact Person Email
- Laurent.GREILLIER@ap-hm.fr
- Site Name
- Institut Bergonié
- Department Name
- Oncologie Médicale
- Contact Person Name
- Antoine Italiano
- Contact Person Email
- a.italiano@bordeaux.unicancer.fr
- Site Name
- Centre Eugène Marquis
- Department Name
- Oncologie médicale
- Contact Person Name
- Thibault De La Motte Rouge
- Contact Person Email
- t.delamotterouge@rennes.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Medical Oncology
- Contact Person Name
- Massard Christophe
- Contact Person Email
- christophe.massard@gustaveroussy.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- Oncologie Médicale
- Contact Person Name
- Carlos Alberto GOMEZ-ROCA
- Contact Person Email
- drci.toulouse@chu-toulouse.fr
- Site Name
- Centr Georges Francois Leclerc
- Department Name
- Medical Oncology
- Contact Person Name
- GHIRINGHELLI Francois
- Contact Person Email
- fghiringhelli@cgfl.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 28-02-2024
- Latest Decision Or Authorization Date
- 03-02-2026
- Processing Time Days
- 706
- Number Of Sites
- 1
- Number Of Participants
- 15
Sites
- Site Name
- University Medical Center Hamburg-Eppendorf
- Department Name
- Dept. Medicine II
- Contact Person Name
- Franziska Westendorf
- Contact Person Email
- f.westendorf@uke.de
Spain
- Earliest CTIS Part Ii Submission Date
- 28-02-2024
- Latest Decision Or Authorization Date
- 09-02-2026
- Processing Time Days
- 712
- Number Of Sites
- 7
- Number Of Participants
- 15
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Irene Brana Garcia
- Contact Person Email
- ibrana@vhio.net
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology
- Contact Person Name
- Luis Paz-Ares Rodriguez
- Contact Person Email
- lpazares@hotmail.com
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Medical Oncology
- Contact Person Name
- Valentina Boni
- Contact Person Email
- valentina.boni@quironsalud.es
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Medical Oncology
- Contact Person Name
- Guzman Alonso Casal
- Contact Person Email
- galonso@nextoncology.eu
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Medical Oncology
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Medical Oncology
- Contact Person Name
- Juan Francisco Rodríguez Moreno
- Contact Person Email
- jfrodriguez@hmhospitales.com
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- Medical Oncology
- Contact Person Name
- David Lorente Estellés
- Contact Person Email
- dlorente@fivo.org
Sponsor
Primary sponsor
- Full Name
- Ideaya Biosciences Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- IDE397
- Active Substance
- MAT2A inhibitor
- Modality
- Small molecule
Related trials
Other published trials that may interest you.